Aytu Biopharma (AYTU) Net Income towards Common Stockholders (2010 - 2025)

Aytu Biopharma (AYTU) has 16 years of Net Income towards Common Stockholders data on file, last reported at $62000.0 in Q2 2025.

• On a quarterly basis, Net Income towards Common Stockholders rose 105.0% year-over-year to $62000.0 in Q2 2025; TTM through Mar 2026 was $62000.0, a 109.1% increase from a year earlier, with the FY2025 full-year figure at $620000.0, up 118.65% from the prior year.
• Net Income towards Common Stockholders for Q2 2025 stood at $62000.0, up from $54000.0 in the prior quarter.
• Over the last five years, Net Income towards Common Stockholders for AYTU reached as high as $7.0 million in Q2 2022 and fell as low as -$53.3 million in Q1 2022.
• Historically, Net Income towards Common Stockholders has averaged -$7.3 million across 5 years, with a median of -$839000.0 in 2023.
• Across the five-year window, Net Income towards Common Stockholders slumped 546.8% in 2021 and soared 158.89% in 2024, its largest moves.
• Year by year, Net Income towards Common Stockholders stood at -$11.5 million in 2021, then soared by 42.04% to -$6.7 million in 2022, then jumped by 87.46% to -$839000.0 in 2023, then surged by 114.66% to $123000.0 in 2024, then tumbled by 49.59% to $62000.0 in 2025.
• Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were $62000.0 in Q2 2025, $54000.0 in Q1 2025, and $123000.0 in Q4 2024.